ABIVAX Société Anonyme (FRA:2X1)
Germany flag Germany · Delayed Price · Currency is EUR
70.30
-0.80 (-1.13%)
Last updated: Sep 29, 2025, 8:19 AM CET

ABIVAX Société Anonyme Company Description

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease.

The company was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme
CountryFrance
Founded2013
IndustryBiological Products, Except Diagnostic Substances
Employees69
CEOMarc M. de Garidel

Contact Details

Address:
7-11 boulevard Haussmann
Paris, 75009
France
Phone33 1 53 83 09 63
Websiteabivax.com

Stock Details

Ticker Symbol2X1
ExchangeFrankfurt Stock Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyEUR
SIC Code2836

Key Executives

NamePosition
Marc M. de GaridelChief Executive Officer
Didier BlondelChief Financial Officer
Patrick MalloyHead of Investor Relations